The CAD primary prevention effect of FGF21 has been represented in subclinical atherosclerosis patients without nonalcoholic fatty liver disease (NAFLD) 45 and patients without a history of DM 46. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.